Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

British Journal of Cancer

Volumn 89, Issue 9, 2003, Pages 1620-1626

  Radny, P ^a   Caroli, U M ^a   Bauer, J ^a   Paul, T ^a   Schlegel, C ^a   Eigentler, T K ^a   Weide, B ^a   Schwarz, M ^a   Garbe, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; Interleukin 2; Intralesional therapy; Soft tissue melanoma metastases

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; DACTINOMYCIN; DIPYRONE; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE; VINDESINE;

ABDOMINAL PAIN; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; ECHOGRAPHY; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTRITIS LIKE SYMPTOM; HEADACHE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; INJECTION PAIN; MALE; MELANOMA; MUSCLE CRAMP; NAUSEA; NIGHT SWEAT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN METASTASIS; SOFT TISSUE METASTASIS; STOMACH DISEASE; STOMACH PAIN; TACHYCARDIA; TISSUE NECROSIS; TREATMENT OUTCOME; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MALE; MELANOMA; MICROSCOPY, CONFOCAL; MIDDLE AGED; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; TREATMENT OUTCOME;

EID: 0344440995     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601320     Document Type: Article

References (29)

1. Abbas AK, Lichtman AH, Pober JS (1994) Effector mechanisms of T cell-mediated immune reactions; Immunity to tumors. In Cellular and molecular immunology, Abbas AK. (ed) pp 271-277, 357-375 Philadelphia: W. B. Saunders
2. Burris HA, Vogel CL, Castro D, Mishra L, Schwarz M, Spencer S, Oakes DD, Korey A, Orenberg EK (1998) Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study. Otolaryngol Head Neck Surg 118: 496-503
3. Chikamatsu K, Reichert TE, Kashii Y, Saito T, Kawashiri S, Yamamoto E, Whiteside TL (1999) Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice. Int J Cancer 82: 532-537
4. Cornejo P, Vanaclocha F, Polimon I, Del Rio R (2000) Intralesional interferon treatment of lentigo maligna. Arch Dermatol 136: 428-430
5. Curiel-Lewandrowski C, Demierre MF (2000) Advances in specific immunotherapy of malignant melanoma. J Am Acad Dermatol 43: 167-188
6. de Gast GC, Klumpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH (2000) Phase I trial of combined immunotherapy with subcutaneous granulocyte-macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 6: 1267-1272
7. Dummer R, Becker JC, Boser B, Hartmann AA, Burg G (1992) Successful therapy of metastatic eccrine poroma using perilesional interferon alfa and interleukin 2. Arch Dermatol 128: 1127-1128
8. Eton O, Buzaid AC, Bedikian AY, Smith TM, Papadopoulos NE, Ellerhorst JA, Hibberts JL, Legha SS, Benjamin RS (2000) A phase II study of 'decrescendo' interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy. Cancer 88: 1703-1709
9. Ferlazzo G, Scisca C, Iemmo R, Cavaliere R, Quartarone G, Adamo V, Frazzetto G, Costa G, Melioli G (1997) Intralesional sonographically guided injections of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of liver tumors: a pilot study. J Immunother 20: 158-163
10. Fierlbeck G, d'Hoedt B, Stroebel W, Stutte H, Bogenschutz O, Rassner G (1992) Intralesional therapy of melanoma metastases with recombinant interferon-beta. Hautarzt 43: 16-21
11. Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R (1996) Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 132: 1353-1357
12. Gutwald J, Groth W, Mahrle G (1994a) Peritumoral administered IL-2-induced tumor regression in melanoma. Pilot study. Hautarzt 45: 536-540
13. Gutwald JG, Groth W, Mahrle G (1994b) Peritumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma. Br J Dermatol 130: 541-542
14. Hajkova R, Indrova M, Jandlova T, Bubenik J, Reinis M (1999) Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors. Folia Biol (Praha) 45: 227-231
15. Hamamoto Y, Nagai K, Ichimiya M, Yamamoto K, Kinoshita E, Muto M (2001) Regressive effect of intralesional injection of a moderate dose of recombinant interleukin-2 on carcinoma erysipeloides from gastric carcinoma. Clin Exp Dermatol 26(1): 42-44
16. Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, Glass LF (1998) Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 83: 148-157
17. Inadomi T, Fujioka A, Suzuki H (1992) A case of malignant haemangioendothelioma showing response to interleukin 2 therapy. Br J Dermatol 127: 442-443
18. Kaplan B, Moy RL (2000) Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma. Dermatol Surg 26(11): 1037-1040
19. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, Goey SH, Gore M, Dorval T, Hancock B, Punt CJ, Dummer R, Avril MF, Brocker EB, Benhammouda A, Eggermont AM, Pritsch M (1998) Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 16: 2921-2929
20. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N (1998) Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16: 1752-1759
21. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA (2001) Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19: 3477-3482
22. Pitts JM, Maloney ME (2000) Therapeutic advances in melanoma. Dermatol Clin 18: 157-167
23. Reeves ME, Coit DG (2000) Melanoma. A multidisciplinary approach for the general surgeon. Surg Clin N Am 80: 581-601
24. Schallreuter KU, Wood JM, Mensing H, Breitbart EW (1991) Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine. Cancer Chemother Pharmacol 29: 167-171
25. Umeda T, Aoki K, Yokoyama A, Ohara H, Hayashi O, Tanaka K, Nishioka K (1998) Changes in immunological parameters after combination adjuvant therapy with intravenous DTIC, ACNU, and VCR, and local injection of IFN-beta (DAV+IFN-beta therapy) into malignant melanoma. J Dermatol 25: 569-572
26. Vaquerano JE, Cadbury P, Treseler P, Sagebiel R, Leong SP (1999) Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony-stimulating factor. Arch Dermatol 135: 1276-1277
27. von Wussow P, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61: 1071-1074
28. Walsh P, Gibbs P, Gonzalez R (2000) Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. J Am Acad Dermatol 42: 480-489
29. Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, Snyderman C, Johnson JT, Myers E, Herberman RB (1993) Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 53: 5654-5662